EPS創健科技(03860.HK)擬285萬元收購三家公司權益
格隆匯9月20日丨EPS創健科技(03860.HK)公佈,於2022年9月20日,公司間接全資附屬公司作為買方擬以現金人民幣285萬元向益新國際醫藥科技收購股份權益,包括合共(i)約95%的目標公司A的全部股權;(ii)目標公司B全部股權的約51%;(iii)目標公司C全部股權的51%。
據悉,目標公司A是一家在中國成立的公司,主要從事臨牀項目管理和監測、醫療數據分析和報吿、患者招募和資源相關事宜的解決方案支持。緊接本次收購完成前,其由賣方持有95%股權,及由北京創立科創醫藥技術開發有限公司,一家在中國成立的公司,據董事所知、所悉和所信其為獨立第三方,持有5%股權。
目標公司B是一家在中國成立的公司,主要從事臨牀試驗數據處理與管理、統計分析與報吿、醫療器械相關安全資訊翻譯、電子數據採集系統開發與支援、動態心電圖監測分析。緊接收購完成前,其由賣方及杭州泰格醫藥科技股份有限公司,一家在中國成立的股份公司及其股票在聯交所(股票代碼:3347)和深圳證券交易所(股票代碼:300347)上市,分別持有51%股權及49%股權。
目標公司C是一家在中國成立的公司,主要從事研究可行性研究等醫學監測、研究中心╱研究人員選擇、隨機化中心、研究監測和質量控制、藥物研究和研究數據管理、註冊協助如申請準備、提交和諮詢、競爭性產品和市場研究、藥品法規諮詢和其他相關開發、營銷和諮詢服務。緊接收購事項完成前,據董事所知、所悉及所信,其由賣方及兩名獨立第三方,分別擁有51%股權及49%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.